Schubert & Co’s Supernus Pharmaceuticals SUPN Stock Holding History

Schubert & Co’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4	Closed	-$145	–	1329
2023 Q1	$145	Buy	+4	New	+$154	﹤0.01%	1574

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Schubert & Co's SUPN Position: Q2 2023 in Review

Schubert & Co sold out of Supernus Pharmaceuticals (SUPN) in Q2 2023, closing a stake of 4 shares — an estimated $145 sold.

Schubert & Co first reported a position in SUPN in Q1 2023 and held it in 1 quarter. The position peaked at $145 in Q1 2023. 249 funds tracked by Wall St. Rank hold SUPN as of Q2 2023.

Schubert & Co reported no remaining Supernus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 4 Supernus Pharmaceuticals shares in Q2 2023, an estimated $145.
Schubert & Co first reported a position in Supernus Pharmaceuticals in Q1 2023 and held it in 1 quarter.
Schubert & Co's Supernus Pharmaceuticals position peaked at $145 in Q1 2023.
249 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.